Relevant and even prescient commentary on news, politics and the economy.

The laying on of scorn

Dan Crawford notes Paul Krugman’s change of heart on the increasing importance of automated systems, in particular robotics: In the past discussions at Angry Bear on the impacts automation might have on our lives, and the economics involved, gathered comments such as “You are a neo luddite”. As if widespread use of automated systems was […]

by Tom aka Rusty Rustbelt Security 101 This week I visited my grandsons’ elementary school four times, three times through the front door and once through a side door. I immediately had the run of the entire building if I so desired. The only line of defense was the receptionist, who gave me a wave because […]

SOCIAL SECURITY and Uncle Sam

by Dale CoberlySOCIAL SECURITY and Uncle Sam moving parts edition Most of us have heard the “phony iou” claim about the Social Security Trust Fund, with its accompanying cartoon of a hapless Uncle Sam furiously borrowing from his left pocket to fill up his right pocket, and stuffing “worthless iou’s” into the left pocket to […]

Many types of tech, not just robots

by Mike Kimel Many types of tech – not just robots – have been affecting and are going to affect the service sector. When someone develops an inexpensive sign you can stick on top of television sets, racks of clothes, or appliances that will change itself whenever someone in the headquarters decides to change the price of the product, […]

Paul Krugman changes his mind on impacts of automation

In the past discussions at Angry Bear on the impacts automation might have on our lives, and the economics   involved,  gathered comments such as “You are a neo luddite”. As if widespread use of automated systems was automatically good for us overall because we would have access to ‘more higher wage and higher skilled […]

Brands and generics pharmaceuticals…

The case is Federal Trade Commission v. Watson Pharmaceuticals et al, No. 12-416.   Via the New York Times comes this note: Last year, for the third time since 2003, the 11th Circuit upheld the agreements as long as the allegedly anticompetitive behavior that results — in this case, keeping the generic drug off the market […]